Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 37

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 37
---
 treated gastric, esophageal, or
gastroesophageal junction (GEJ) adenocarcinoma. This investigator-sponsored study, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, is evaluating agenT-797 in combination with
botensilimab (a novel Fc-enhanced CTLA-4 inhibitor), balstilimab (anti–PD-1), ramucirumab, and paclitaxel. The study, which
aims to enroll approximately 38 patients, was highlighted at the ASCO GI Symposium in January 2025 followed by a presentation of the immune modulating and clinical activity of the combination at the inaugural
AACR-IO congress in February of 2025 and additional data are anticipated in the impending months.

Beyond oncology, agenT-797 has shown promise in acute pulmonary immune failure. In a clinical trial
(NCT04582201) evaluating patients with moderate to severe viral acute respiratory distress syndrome (ARDS), agenT-797 was associated with overall survival exceeding 70%. In the subgroup of patients receiving
veno-venous extracorporeal membrane oxygenation (VV ECMO), survival was 80%—compared to a historical ICU control survival rate of approximately 10%. These results were published in Nature Communications in February 2024. Additional
clinical and translational findings from this program were presented at the American Thoracic Society (ATS) Annual Meetings in 2023 and 2024. We intend to advance development of agenT-797 for viral ARDS in a
large-scale, externally funded platform trial.

In parallel, we are developing a pipeline of next-generation, engineered iNKT cell
therapies designed to enhance tumor targeting, overcome resistance, and remodel the tumor microenvironment. Our two most advanced preclinical candidates are MiNK-413, an
IL-15 armored CAR-iNKT targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15
armored CAR-iNKT targeting fibroblast activation protein (FAP). Both programs have shown robust preclinical activity and competitive manufacturing advantages. MiNK-413
has demonstrated tumor clearance and improved persistence in preclinical models of hematologic malignancy. MiNK-215 has shown potent activity in lung and colorectal cancer models, including organoid systems
with liver metastases, where it enhanced T cell-mediated killing, depleted suppressive F